Trials / Recruiting
RecruitingNCT05447702
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- West China Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | Intravenous (IV) infusion |
| DRUG | Apatinib | po. |
| DRUG | Nab-paclitaxel | IV infusion. |
| DRUG | Epirubicin | IV infusion. |
| DRUG | Cyclophosphamide | IV infusion. |
Timeline
- Start date
- 2022-11-01
- Primary completion
- 2023-12-31
- Completion
- 2026-12-31
- First posted
- 2022-07-07
- Last updated
- 2023-05-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05447702. Inclusion in this directory is not an endorsement.